Compare
LifeMD, Inc. vs Airsculpt Technologies, Inc. vs Cardiff Lexington Corp
| Latest fiscal year | LifeMD, Inc. LFMD | Airsculpt Technologies, Inc. AIRS | Cardiff Lexington Corp CDIX |
|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $194.06M | $151.82M | $11.54M |
| Revenue growth (YoY) | +25.3% | -15.8% | +39.5% |
| Gross margin | 85.7% | n/a | 62.5% |
| Operating margin | -4.0% | -7.6% | 9.5% |
| Net margin | 7.4% | -7.7% | -47.7% |
| Net income | $14.35M | -$11.67M | -$5.51M |
| EPS (Diluted) | $0.25 | -$0.19 | n/a |
| Operating cash flow | $8.28M | $3.10M | -$2.85M |
| Free cash flow | $6.41M | $692.0K | n/a |
| Cash & equivalents | n/a | $8.45M | n/a |
| Total assets | $70.41M | $187.30M | $29.09M |
| Total liabilities | $47.25M | $99.59M | $26.01M |
| Shareholders' equity | $23.16M | $87.71M | -$2.47M |
| Return on year-end equity | 62.0% | -13.3% | n/a |
| Shares outstanding | 46.66M | 64.46M | 13.70M |
Revenue, most recent five fiscal years
| Fiscal year | LifeMD, Inc. | Airsculpt Technologies, Inc. | Cardiff Lexington Corp |
|---|---|---|---|
| Latest | $194.06M Ended 2025-12-31 | $151.82M Ended 2025-12-31 | $11.54M Ended 2025-12-31 |
| 1 year earlier | $154.82M Ended 2024-12-31 | $180.35M Ended 2024-12-31 | $8.27M Ended 2024-12-31 |
| 2 years earlier | $152.55M Ended 2023-12-31 | $195.92M Ended 2023-12-31 | $11.85M Ended 2023-12-31 |
| 3 years earlier | $119.03M Ended 2022-12-31 | $168.79M Ended 2022-12-31 | $10.69M Ended 2022-12-31 |
| 4 years earlier | $92.88M Ended 2021-12-31 | $133.31M Ended 2021-12-31 | $9.88M Ended 2021-12-31 |